Alkem Laboratories Limited (NSE: ALKEM) announced the launch of NeuCeno (cenobamate), a groundbreaking anti-seizure medication for the treatment of partial-onset seizures in adult patients. This marks the first time cenobamate is being introduced in India, signifying a major step forward in managing epilepsy. NeuCeno is available in various strengths, offering a once-daily oral therapy option. With an estimated 9.4 million people in India living with epilepsy, the launch of NeuCeno aims to address the unmet medical needs and improve the quality of life for patients.

Unique Mechanism of Action

NeuCeno (cenobamate) operates through a dual mechanism of action, selectively inhibiting the persistent sodium current and enhancing the brain’s natural inhibitory signaling. In clinical studies, adjunctive cenobamate demonstrated up to a 78% reduction in seizure frequency, with up to 30% of patients achieving seizure freedom during the maintenance phase. This significant efficacy underscores the potential of NeuCeno to transform treatment outcomes for patients with uncontrolled focal seizures.

Commitment to Patient Care

Sandeep Singh, Managing Director of Alkem Laboratories Limited, emphasized the company’s dedication to advancing high-quality, affordable medicines. He stated, ‘People living with epilepsy and their caregivers face significant challenges in achieving effective seizure control. Cenobamate has the potential to transform treatment outcomes towards delivering better epilepsy management.’ Alkem reaffirms its commitment to improving patient care by providing an important therapeutic option and supporting healthcare professionals in making informed treatment decisions.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Alkem Laboratories Limited

Alkem Laboratories Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Alkem trades in the lower quarter of its 52-week range. Not a single revenue dip or loss quarter in five years — this is a business built to last through cycles. The PEG of 0.87 signals undervaluation relative to growth. It is a potential re-rating candidate. The stock sits at 12% of its 52-week range, close to annual lows. Historically, value investors build positions at these levels — though cheap stocks can stay cheap. Revenue grows at 8.3% and profits at 32.7%. The business is in good shape. Moreover, a stock that does not move despite strong fundamentals often offers better value than one already priced for perfection. Check Fundamentals of Alkem Laboratories Limited.

Alkem Laboratories Limited (NSE: ALKEM) has announced the launch of Renocia Exo™, India’s first patented Ginsenoside exosome-based hair growth serum. This innovative product aims to address hair loss through a comprehensive scientific approach. Unlike conventional treatments, Renocia Exo™ focuses on supporting the biology of the hair follicle by integrating Ginsenoside phyto-exosomes, biomimetic peptides, copper peptides, and stem cell-supportive actives.

Innovative Approach to Hair Loss Management

Hair loss has become a significant concern in India, affecting both aging adults and younger individuals due to genetics, lifestyle changes, and environmental stressors. Alkem’s new product, Renocia Exo™, is developed to support the health and vitality of the hair follicle through multiple regenerative technologies. The formulation supports several interconnected biological processes associated with healthy hair follicle function, promoting a favorable environment for stronger, healthier hair over time.

Comprehensive Scientific Formulation

Renocia Exo™ is designed to support multiple signaling pathways involved in hair follicle activity. Its lightweight, cosmetically elegant composition is free from alcohol, sulphates, silicones, parabens, and mineral oil, making it suitable for regular use as part of dermatologist-guided hair loss management. The product’s innovative approach marks a significant step forward in the science of hair restoration, addressing the complex interplay of biological mechanisms that drive hair thinning.

With the launch of Renocia Exo™, Alkem continues to strengthen its dermatology portfolio by translating emerging scientific insights into practical therapeutic innovations that address evolving patient needs. This launch underscores Alkem’s commitment to inspiring healthier lives through advanced scientific research and development.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Alkem Laboratories Limited

Alkem Laboratories Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Alkem trades in the lower quarter of its 52-week range. Not a single revenue dip or loss quarter in five years — this is a business built to last through cycles. The PEG of 0.89 signals undervaluation relative to growth. It is a potential re-rating candidate. The stock sits at 20% of its 52-week range, close to annual lows. Historically, value investors build positions at these levels — though cheap stocks can stay cheap. Revenue grows at 8.3% and profits at 32.7%. The business is in good shape. Moreover, a stock that does not move despite strong fundamentals often offers better value than one already priced for perfection. Check Fundamentals of Alkem Laboratories Limited.

Alkem Laboratories Limited (NSE: ALKEM) today announced its standalone and consolidated financial results for the first quarter ended June 30, 2026. The Board of Directors took record of these results at its meeting held in Mumbai today. Commenting on the results, Mr. Sandeep Singh, MD of Alkem, said, “We have started FY27 on a steady note, with healthy growth across our India and international businesses. Our India business continued to outperform the market, while the strong growth in our non-US international markets was encouraging. However, there are areas where we need to improve, particularly in strengthening execution, addressing operational and regulatory priorities, and improving the consistency of performance across our businesses. We are also investing in R&D, MedTech and Biotech as we build our next phase of growth. Our focus will be to strengthen the core, address the areas that need improvement and build these newer opportunities in a disciplined manner.”

Q1 FY27 Key Financial Highlights

• Total Revenue from Operations was ₹37,402 million, with YoY growth of 10.9%. o India sales were ₹24,978 million, YoY growth of 10.3%. o International sales were ₹12,223 million, with YoY growth of 16.0%.

Operational Highlights

Domestic Business Key Highlights: The contribution of domestic sales to total sales was 67.1% vs. 68.2% in Q1 FY26. According to IQVIA (SSA) data, for Q1 FY27: o The Company registered a growth of 13.2% YoY vs Indian Pharmaceutical Market (IPM), which grew by 12.2 %, 100 bps outperformance.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Alkem Laboratories Limited

Alkem Laboratories Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Alkem moves sideways over three months, with neither buyers nor sellers taking control. Not a single revenue dip or loss quarter in five years — this is a business built to last through cycles. The PEG of 0.87 signals undervaluation relative to growth. It is a potential re-rating candidate. Buyers show up with 1.5x the volume of sellers. Moreover, they dominated on 17 of recent sessions versus 13 for sellers — a healthy accumulation pattern. Revenue grows at 8.3% and profits at 32.7%. The business is in good shape. Moreover, a stock that does not move despite strong fundamentals often offers better value than one already priced for perfection. Check Fundamentals of Alkem Laboratories Limited.